Last reviewed · How we verify
Olanzapine+NK-1 RA+5-HT3 RA
Olanzapine+NK-1 RA+5-HT3 RA is a Combination antipsychotic + antiemetic Small molecule drug developed by Fifth Affiliated Hospital, Sun Yat-Sen University. It is currently in Phase 3 development for Chemotherapy-induced nausea and vomiting (CINV) in cancer patients, Nausea and vomiting in patients with concurrent psychiatric conditions.
This combination blocks dopamine/serotonin (olanzapine), substance P signaling (NK-1 RA), and serotonin 5-HT3 receptors to reduce nausea, vomiting, and potentially improve psychiatric symptoms.
This combination blocks dopamine/serotonin (olanzapine), substance P signaling (NK-1 RA), and serotonin 5-HT3 receptors to reduce nausea, vomiting, and potentially improve psychiatric symptoms. Used for Chemotherapy-induced nausea and vomiting (CINV) in cancer patients, Nausea and vomiting in patients with concurrent psychiatric conditions.
At a glance
| Generic name | Olanzapine+NK-1 RA+5-HT3 RA |
|---|---|
| Sponsor | Fifth Affiliated Hospital, Sun Yat-Sen University |
| Drug class | Combination antipsychotic + antiemetic |
| Target | Dopamine D2, serotonin 5-HT2A (olanzapine); Substance P/NK-1 receptor (NK-1 RA); 5-HT3 receptor (5-HT3 RA) |
| Modality | Small molecule |
| Therapeutic area | Oncology (supportive care) / Psychiatry |
| Phase | Phase 3 |
Mechanism of action
Olanzapine is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. NK-1 receptor antagonists block substance P signaling, which plays a role in nausea and emesis. 5-HT3 receptor antagonists (ondansetron-class) directly block chemoreceptor trigger zone signaling. The combination targets multiple pathways involved in chemotherapy-induced nausea and vomiting (CINV) and may address concurrent psychiatric symptoms.
Approved indications
- Chemotherapy-induced nausea and vomiting (CINV) in cancer patients
- Nausea and vomiting in patients with concurrent psychiatric conditions
Common side effects
- Sedation
- Weight gain
- Metabolic effects (hyperglycemia, dyslipidemia)
- Headache
- Constipation
- Dizziness
Key clinical trials
- NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens (PHASE3)
- Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Olanzapine+NK-1 RA+5-HT3 RA CI brief — competitive landscape report
- Olanzapine+NK-1 RA+5-HT3 RA updates RSS · CI watch RSS
- Fifth Affiliated Hospital, Sun Yat-Sen University portfolio CI
Frequently asked questions about Olanzapine+NK-1 RA+5-HT3 RA
What is Olanzapine+NK-1 RA+5-HT3 RA?
How does Olanzapine+NK-1 RA+5-HT3 RA work?
What is Olanzapine+NK-1 RA+5-HT3 RA used for?
Who makes Olanzapine+NK-1 RA+5-HT3 RA?
What drug class is Olanzapine+NK-1 RA+5-HT3 RA in?
What development phase is Olanzapine+NK-1 RA+5-HT3 RA in?
What are the side effects of Olanzapine+NK-1 RA+5-HT3 RA?
What does Olanzapine+NK-1 RA+5-HT3 RA target?
Related
- Drug class: All Combination antipsychotic + antiemetic drugs
- Target: All drugs targeting Dopamine D2, serotonin 5-HT2A (olanzapine); Substance P/NK-1 receptor (NK-1 RA); 5-HT3 receptor (5-HT3 RA)
- Manufacturer: Fifth Affiliated Hospital, Sun Yat-Sen University — full pipeline
- Therapeutic area: All drugs in Oncology (supportive care) / Psychiatry
- Indication: Drugs for Chemotherapy-induced nausea and vomiting (CINV) in cancer patients
- Indication: Drugs for Nausea and vomiting in patients with concurrent psychiatric conditions
- Compare: Olanzapine+NK-1 RA+5-HT3 RA vs similar drugs
- Pricing: Olanzapine+NK-1 RA+5-HT3 RA cost, discount & access